Tenax Q2 Loss Widens on Trial Costs, Cash Runway Extended to Q2 2028, Supply Deal Secured
TENX has more than doubled off its 52-week low of $5.78 on light trading volume (0.4× avg).
Summary
Tenax Q2 loss widened to $17.8M on higher trial spending, but cash runway extends to Q2 2028. A new Orion supply deal secures commercial manufacturing ahead of pivotal Phase 3 data in August.
Key Events · Earnings and Guidance · TENX
-
Q2 Net Loss Widens on Trial Costs
Net loss of $17.8M vs. $10.8M in Q2 2025, driven by a 110% increase in R&D to $12.9M as the LEVEL and LEVEL-2 Phase 3 trials advance.
-
Cash Runway Extended to Q2 2028
Cash and equivalents of $118.0M at June 30, plus $8.1M in subsequent warrant exercises, fund operations through Q2 2028 — beyond the expected topline LEVEL data in August 2026.
-
Orion Supply Agreement Finalized
A long-term supply agreement with Orion was executed on June 29, 2026, securing commercial manufacturing of oral levosimendan and sharing industrialization costs, with Tenax bearing a portion of Step 2 scale-up expenses.
-
Significant Warrant Exercises Dilute Shares
Shares outstanding surged to 31.9M from 9.3M at year-end 2025 due to exercises of pre-funded warrants and warrants, bringing in $43.8M in cash but increasing the share count by over 240%.
Analysis · TENX · Life Sciences
A $17.8 million net loss for Q2 2026 reflects a doubling of R&D expenses as Tenax Therapeutics advances its Phase 3 levosimendan trials. With $118 million in cash at quarter-end and an additional $8.1 million from subsequent warrant exercises, the company has extended its cash runway to Q2 2028 — a critical buffer ahead of the topline LEVEL data expected in August. The 10-Q also details a finalized supply agreement with Orion that secures commercial manufacturing and includes cost-sharing for industrialization, de-risking the path to potential approval. The sharp increase in shares outstanding — from 9.3 million to 31.9 million — reflects heavy warrant exercises, diluting existing holders but providing non-dilutive cash. With a pivotal data readout imminent, the financial position and supply chain are now locked in.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 977 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TENX was trading at $14.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $388.6M. The 52-week trading range was $5.78 to $19.40. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.